Artennua is an optimized version of Artemisia annua – a medicinal plant used for centuries in Chinese Medicine and is the source of artemisinin, the molecule recommended by the WHO to treat malaria. Artemisinin, its derivatives, and other secondary metabolites have the potential to treat many other afflictions; however, Artemisia annua produces very low quantities of artemisinin and thus global supply is limited. At Sequentia we are scientists and social entrepreneurs; we have used natural plant biopharming methods to improve the characteristics of the Artemisia annua plant so that its benefits can be exploited.
Another important article suggesting interesting conclusions about artemisia annua plant and cancer as it shows the major efficacy of the extract derived from the plant compared to the pure artemisinin (SSA, Semi Syntetic Artemisinin) against dogs cancer (osteosarcoma). The study has appeared this month on Pubmed and was conducted by researchers from the University of Bologna…
A new study reveals how Artemisia annua unique molecule artemisinin and its derivatives are able not only to treat parasitic disorders but also to balance the immune system that directly benefits the host.
The newspaper interviews our CEO of Biotech Tricopharming Research Luis Matias, who explains how our Artennua product works and what growth and development prospects we expect. Luis also focuses on the strategic importance of Canary Islands for Artennua production. Indeed, Artennua could become an important crop for the region given its valuable and international trade…
